Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study

Prostate

Prostate
N/A
Chang, Sam
VICCURO1734

MRI-Ultrasound Fusion Targeted Prostate Biopsies - Quality Control & Performance Improvement

Prostate

Prostate
N/A
Resnick, Matthew
VICCURO1680

Cognitive Assessment and MRI Program in Identifying Cognitive Effects of Androgen Receptor Directed Therapies in Patients with Advanced Prostate Cancer

Prostate

This clinical trial studies how well cognitive assessment and magnetic resonance imaging (MRI) program work in identifying cognitive effects of androgen receptor directed therapies such as abiraterone acetate and enzalutamide in patients with prostate cancer that has spread from where it started to other places in the body. Cognitive assessment and MRI program may help to assess the cognitive function of patients during treatment and identify genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
Prostate
N/A
Moses, Kelvin
NCT03016741
VICCURO16133

Prospective Observational Trial of an Absorbable Hydrogel Spacer in Prostate Cancer Radiotherapy

Prostate

Prostate
N/A
Newman, Neil
VICCURO16112

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate

This is a two-arm, open label Phase 1b / 2 study with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone / prednisone in male patients with metastatic Castration Resistant Prostate Cancer. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone / prednisone. Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone / prednisone vs either enzalutamide or abiraterone / prednisone as a control arm.
Prostate
I/II
Moses, Kelvin
NCT03480646
VICCURO18155

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Prostate

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Prostate
III
Moses, Kelvin
NCT03395197
VICCURO17115

Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer

Prostate

This phase III trial studies whether the addition of definitive treatment (radiation or surgical removal) of the primary tumor to standard systemic therapy for patients with prostate cancer, may help prevent the cancer from the spreading to other parts of their body. Removing the prostate by either surgery or radiation therapy in addition to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Prostate
III
Keegan, Kirk
NCT03678025
ECOGUROS1802

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients with Prostate Cancer

Prostate

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Prostate
II
Planz, Virginia
NCT03697148
ECOGUROEA8171

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: